Core Insights - Biotech shares experienced significant movements in after-hours trading, with Sarepta Therapeutics leading due to anticipated trial data and other companies benefiting from recent clinical and regulatory updates [1] Company Summaries - Sarepta Therapeutics Inc. (SRPT) saw a surge of 9.65% to $23.17, driven by anticipation for a webcast on January 26, 2026, where three-year topline results from its Phase 3 trial of ELEVIDYS for Duchenne muscular dystrophy will be presented, potentially pivotal for its gene therapy program [2] - Fractyl Health, Inc. (GUTS) increased by 7.66% to $2.25, indicating speculative interest despite no new company news, suggesting momentum-driven trading [3] - Greenwich LifeSciences, Inc. (GLSI) advanced 2.08% to $26.00 following FDA approval of the first commercial lot of GP2 vials for the FLAMINGO-01 trial, marking a significant step in its commercialization efforts with the potential to prepare approximately 200,000 doses [4] - Anebulo Pharmaceuticals, Inc. (ANEB) rose 8.41% to $1.16, attracting buyers despite no new updates, reflecting investor interest [5] - OmniAb, Inc. (OABI) gained 4.59% to $2.05, similar to Anebulo, indicating broader investor interest in the biotech sector without fresh news [6] - Trevi Therapeutics, Inc. (TRVI) added 3.40% to $10.33 after publishing results from its Phase 2b CORAL trial in a peer-reviewed journal, enhancing credibility and investor enthusiasm [7] - AEON Biopharma, Inc. (AEON) edged up 1.80% to $1.13, confirming a meeting with the FDA and securing shareholder approval for financing transactions, simplifying its capital structure ahead of a second PIPE financing closing expected around January 27, 2026 [8]

Core Insights - U.S. stock futures are lower, with Dow futures dropping over 100 points on Thursday [1] - Immuneering Corp's shares fell 20.7% to $6.61 in pre-market trading following the announcement of updated survival and safety data from its Phase 2a trial for pancreatic cancer [1] Company Movements - Elme Communities shares decreased 82.8% to $2.98 in pre-market trading [3] - Erasca Inc shares fell 14% to $4.45 after a previous rise of 42% on Wednesday [3] - Phathom Pharmaceuticals Inc shares dropped 13.7% to $15.60 after announcing a $130 million public offering [3] - United Microelectronics Corp shares declined 6.3% to $8.37 after a 10% increase on Wednesday due to reported sales growth [3] - Canadian Solar Inc shares decreased 6.1% to $20.68 following a proposed $200 million public offering [3] - Trevi Therapeutics Inc shares fell 6.1% to $11.00 in pre-market trading [3] - Revolution Medicines Inc shares dipped 6% to $96.57 after reports that AbbVie is not in discussions with the company [3] - Sibanye Stillwater Ltd shares decreased 5.7% to $15.01 in pre-market trading [3] - Vanda Pharmaceuticals Inc shares fell 5% to $8.11 despite FDA approval of its product to prevent motion-induced vomiting [3] - Logitech International SA shares declined 4.8% to $94.91 ahead of its third quarter fiscal year 2026 financial results release [3]

Core Insights - Trevi Therapeutics is advancing its investigational therapy Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [1][4][5] Company Updates - The company has scheduled an End-of-Phase 2 meeting with the FDA in the first quarter of 2026 to discuss the clinical development and regulatory pathway for Haduvio [1][7] - A Phase 2b trial for RCC is planned to initiate in the first half of 2026 [1][7] - David Hastings, the new Chief Financial Officer, will attend the LifeSci Partners Corporate Access Event alongside senior management [7] Product Information - Haduvio (oral nalbuphine ER) is the first investigational therapy to show a statistically significant reduction in cough frequency in clinical trials for both IPF chronic cough and RCC [4] - The therapy acts on the cough reflex arc as a kappa agonist and mu antagonist, targeting opioid receptors involved in chronic cough control [4] Market Need - There are approximately 150,000 U.S. patients with IPF, with two-thirds experiencing uncontrolled chronic cough [5] - About 228,000 U.S. patients have non-IPF ILD, with 50-60% suffering from uncontrolled chronic cough [5] - RCC affects an estimated 2-3 million U.S. patients and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions [6]

Leadership Change - Trevi Therapeutics, Inc. appointed David Hastings as Chief Financial Officer, effective January 6, 2026, marking a significant leadership change as the company transitions into a more advanced development stage [2] - Hastings brings 25 years of financial leadership experience in public life sciences companies and has helped raise $2 billion in equity and debt financing, aligning with Trevi's growth strategy [2] Clinical Development - Trevi is preparing to request an End-of-Phase 2 meeting with the FDA in Q4 2025 for its lead program targeting chronic cough associated with idiopathic pulmonary fibrosis (IPF), having completed key Phase 2 work [3] - The company expects to initiate a Phase 3 program in the first half of 2026, reinforcing its transition into this critical phase of development [3] Safety and Efficacy Studies - The ongoing Phase 1 TIDAL study in IPF patients has shown no safety signals, and a completed drug-drug interaction study confirmed that nalbuphine ER can be safely co-administered with standard antifibrotic therapies [4] - Trevi has presented topline Phase 2b CORAL data, enhancing clinical and investor visibility [4] Financial Position - As of the end of Q3 2025, Trevi Therapeutics reported a cash balance of $194.9 million, positioning the company well to capitalize on its clinical momentum [5] - The company is focused on developing Haduvio, an oral extended-release therapy for chronic cough across IPF, Non-IPF ILD, and refractory chronic cough [5]

Market Overview - The article discusses the potential for strong market momentum to continue into 2026, with a focus on identifying the next wave of multibagger stocks [1][2] - Chris Toomey from Morgan Stanley expects a solid year for markets in 2026, driven by secular tailwinds, improving earnings visibility, supportive fiscal and monetary policies, and a revival of market enthusiasm due to deregulation and increased M&A activity [3][4] Investment Strategy - Toomey emphasizes the importance of market leadership broadening, suggesting that previously overlooked sectors may present new investment opportunities, moving beyond the dominance of mega-cap technology stocks [5] - The methodology for selecting the best multibagger stocks includes filtering for stocks with a market capitalization over $500 million, at least 150% returns over the past year, and a minimum of 50% upside potential [7] Company Highlights CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Market Cap: $696.38 million, with a 1-year price return of 263.72% and an upside potential of 58.20% [9] - 90% of analysts are bullish on CTMX, with a median price target of $6.50, indicating a healthy upside potential [10] - H.C. Wainwright has reiterated a "Buy" rating with a $10.00 price target, anticipating critical data for the CX-2051 therapy in colorectal cancer [11] - The firm outlines performance benchmarks for CX-2051, categorizing potential outcomes into "slam dunk," "bull," and "bear" scenarios based on expected response rates and survival metrics [12] - The company is progressing with its CX-2051 program, with enrollment nearing 100 patients ahead of a planned Phase 1 update in Q1 2026 [13][14] Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Market Cap: $1.59 billion, with a 1-year price return of 169.11% and an upside potential of 73.40% [15] - The appointment of David Hastings as CFO is seen as a strategic move to support the company's transition into advanced development stages [16] - Trevi is preparing for a Phase 3 program for Haduvio in chronic cough associated with idiopathic pulmonary fibrosis (IPF), with an End-of-Phase 2 meeting with the FDA expected in Q4 2025 [17] - Ongoing studies have shown no safety signals, and the company has a cash balance of $194.9 million as of Q3 2025, positioning it well for future clinical developments [18][19]

Group 1 - Viking Global Investors LP made significant reductions in high-profile holdings during Q2 2025, indicating a shift away from higher-beta growth stocks [1][2] - The most notable reduction was in Meta Platforms Inc. (META), where Viking cut its stake by nearly 82%, reflecting caution on mega-cap tech valuations despite Meta's advancements in AI and digital advertising [2][3] - The overall strategy appears to be a repositioning away from higher-beta and cyclical growth names, suggesting a cautious approach amid a volatile macroeconomic environment [3] Group 2 - Viking executed full exits from several major blue-chip and financial holdings, indicating a comprehensive reallocation of capital [4] - Significant disposals included a $1.12 billion stake in UnitedHealth Group, a $1.05 billion stake in Intuit, a $699 million stake in Netflix, a $589 million stake in Chubb Limited, and a $552 million stake in Intercontinental Exchange [7]

Core Insights - Trevi Therapeutics Inc. (NASDAQ:TRVI) is highlighted as a promising multibagger stock, with Morgan Stanley initiating coverage with an Overweight rating and an $18 price target [1][2] Group 1: Haduvio's Market Potential - Haduvio, Trevi's extended-release formulation of nalbuphine, is being developed to treat chronic cough, addressing a significant unmet medical need in a market with limited existing therapies [2][3] - The analyst estimates that Haduvio could represent a multi-billion-dollar opportunity for Trevi, with increasing interest in the pharmaceutical sector further supporting this potential [3] Group 2: Competitive Landscape - Large pharmaceutical companies like GSK and Merck have already engaged in billion-dollar partnerships in the chronic cough treatment space, indicating that Trevi could benefit from increased attention and investment in this area [3]

Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) [4][5] - Haduvio is the first therapy in clinical development to demonstrate a statistically significant reduction in chronic cough for both IPF and RCC patients [4] Market Need - Chronic cough affects up to 85% of the 140,000 U.S. IPF patients, leading to severe impacts on their quality of life, including social, physical, and psychological decline [5] - Refractory chronic cough, affecting approximately 2-3 million patients in the U.S., has no approved therapies and is characterized by a persistent cough lasting over 8 weeks despite treatment for underlying conditions [6] Upcoming Events - Trevi will participate in several investor conferences in April 2025, including: - 24th Annual Needham Virtual Healthcare Conference on April 7, with a corporate presentation by Jennifer Good, President and CEO [2] - Jones Healthcare and Technology Innovation Conference on April 9, with a presentation by Jennifer Good [3] - Piper Sandler Spring Biopharma Symposium on April 16-17, featuring Jennifer Good and James Cassella [4] Product Details - Haduvio acts on the cough reflex arc as a kappa agonist and mu antagonist, targeting opioid receptors involved in cough hypersensitivity [4] - The safety and efficacy of Haduvio have not yet been evaluated by any regulatory authority [7]